One-Child study tracks Ngenla's Long-Term safety for growth hormone deficiency
NCT ID NCT05602766
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study follows one child with growth hormone deficiency (GHD) who is taking Ngenla for the first time. The goal is to check the drug's long-term safety and how well it helps growth. The child will be monitored until November 2027.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROWTH HORMONE DEFICIENCY WITHOUT EPIPHYSEAL CLOSURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.